India to United Arab Emirates: Antidandruff Export Trade Route

To import antidandruff formulations into the UAE, manufacturers must obtain approval from the Ministry of Health and Prevention (MOHAP). The registration process includes:

• Dossier Submission: A Common Technical Document (CTD) or electronic CTD (eCTD) format is required, encompassing detailed information on product quality, safety, and efficacy.

• Certificate of Pharmaceutical Product (COPP): Issued by the national regulatory authority of the exporting country, this certificate must be authenticated and legalized for use in the UAE. The legalization process involves authentication by the U.S. Department of State and the UAE Embassy.

• Good Manufacturing Practice (GMP) Certificate: A valid GMP certificate from the manufacturing facility is mandatory, confirming adherence to international manufacturing standards.

• Product Samples: Submission of product samples for laboratory analysis to verify compliance with UAE standards.

• Labeling Requirements: Labels must include product name, manufacturer details, ingredients, dosage instructions, production and expiry dates, batch number, and storage conditions.

The approval timeline varies but typically ranges from several months to over a year, depending on the completeness of the submission and the complexity of the product. Product registration fees are determined by MOHAP and may vary based on the product category and registration type.

Indian manufacturers exporting antidandruff formulations to the UAE must comply with the following GMP standards:

• WHO-GMP Certification: Facilities must hold a valid WHO-GMP certificate, ensuring that products are consistently produced and controlled according to quality standards.

• GMP Certificate Attestation: The GMP certificate must be attested by the UAE Embassy in India to validate its authenticity for UAE authorities.

As of March 2026, specific details regarding recent inspections or regulatory actions by the Gulf Health Council against Indian pharmaceutical companies are not publicly disclosed. Manufacturers are advised to maintain compliance with all regulatory requirements to avoid potential issues.

In the past 18 months, several regulatory changes have impacted pharmaceutical imports into the UAE:

• New Pharmacy Law (Law No. 11 of 2023): Effective from 2023, this law mandates that Marketing Authorization Holders (MAHs) appoint at least two pharmaceutical establishments for importing medical products into the UAE and one or more establishments for distribution. The practical application of these requirements awaits further clarification from MOHAP.

• Establishment of the UAE Drug Authority: In 2023, the UAE Drug Authority was established to enhance public health and position the UAE as a global center for pharmaceutical and medical industries. This authority oversees product approvals, surveillance, and regulatory compliance.

These developments underscore the UAE's commitment to strengthening its pharmaceutical regulatory framework, affecting importers and manufacturers aiming to enter the UAE market.

The United Arab Emirates (UAE) pharmaceutical market is projected to reach USD 8.0 million by 2033, growing at a compound annual growth rate (CAGR) of 6.1% from 2026 to 2033. Within this market, the demand for antidandruff formulations is influenced by factors such as increasing awareness of personal hygiene, rising incidences of scalp-related conditions, and a growing preference for over-the-counter (OTC) solutions. In 2025, the UAE's OTC pharmaceuticals market is expected to generate revenue of USD 634.68 million, with a projected annual growth rate of 1.04% from 2025 to 2030. The antidandruff segment, encompassing shampoos and related treatments, contributes significantly to this market. The UAE relies on both imports and domestic manufacturing to meet the demand for antidandruff formulations. Local pharmaceutical companies, such as Julphar Pharmaceuticals and Neopharma, play a crucial role in supplying these products. However, specific data on the proportion of imports versus domestic production for antidandruff formulations is not readily available.

The UAE adheres to the Gulf Cooperation Council (GCC) Common Customs Tariff, which sets a standard import duty rate of 5% for most goods. However, pharmaceutical products, including those classified under HS code 30039011, are generally exempt from import duties in the UAE. Additionally, the UAE has a de minimis threshold of AED 300 for low-value shipments, below which duties and taxes are not collected. The UAE and India signed a Comprehensive Economic Partnership Agreement (CEPA) in February 2022, which came into effect in May 2022. This agreement aims to enhance trade relations between the two countries, potentially impacting tariff structures and providing preferential treatment for certain goods, including pharmaceuticals. However, specific details regarding antidandruff formulations under this agreement are not specified.

India is a key supplier of antidandruff formulations to the UAE, with companies like Brihans Natural Products Limited exporting products to buyers such as the Dubai Herbal Treatment Centre. Other major countries supplying antidandruff formulations to the UAE include Germany and Malaysia. India's share of the UAE's total antidandruff imports is significant, though exact figures are not specified. In terms of pricing, Indian antidandruff formulations are competitively priced compared to those from China and European Union manufacturers. For instance, the average import price for products under HS code 30039011 in the UAE was $1.62 per unit, with Indian products often priced below this average. This competitive pricing, combined with the quality of Indian pharmaceutical products, positions India favorably in the UAE antidandruff market.

India supplies approximately 20% of the global demand for generic medicines, producing over 60,000 generic brands across 60 therapeutic categories. The country has surpassed the United States in the number of FDA-registered generic manufacturing sites, with 752 FDA-approved, 2,050 WHO-GMP-certified, and 286 EDQM-approved plants as of 2024. This extensive infrastructure enables large-scale production of finished dosage forms, including tablets, capsules, and syrups containing antidandruff agents. India's cost-effective production is driven by factors such as lower labor costs, economies of scale, and a robust supply chain, allowing for competitive pricing without compromising quality.

India's pharmaceutical exports have grown at 9%, nearly double the global average, indicating strong global acceptance. While specific price per unit data for antidandruff formulations is not readily available, India's cost-effective production capabilities often result in more competitive pricing compared to China and the European Union. The country's adherence to international regulatory standards, evidenced by numerous FDA and WHO-GMP certifications, ensures high-quality products. In contrast, the European Union's branded generics are perceived as high-quality but come at a premium price. Local manufacturers in the UAE may offer faster delivery times but might lack the economies of scale and cost advantages that Indian manufacturers provide.

India's pharmaceutical industry has demonstrated a strong track record in supply reliability, supported by a vast manufacturing base and compliance with international regulatory standards. The country has over 670 US FDA-approved facilities, many specializing in sterile injectable production, indicating robust capacity for finished dosage forms. While specific data on packaging and cold chain capabilities for antidandruff formulations are limited, India's experience in exporting to over 200 countries suggests well-established logistics infrastructure. There have been no significant supply disruptions reported in recent years, and the industry continues to expand, with the pharmaceutical manufacturing market projected to reach USD 35.38 billion by 2030, growing at a CAGR of 10.5%.

• Implement a Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure a consistent supply of antidandruff formulations.

• Negotiate Favorable Minimum Order Quantities (MOQs): While MOQs can vary, Indian manufacturers often offer flexibility, especially for long-term partnerships. Clearly define MOQs to align with your demand forecasts.

• Establish Clear Payment Terms: Common payment terms in India-UAE pharmaceutical trade include Letters of Credit (LC) and Telegraphic Transfers (TT). Negotiate terms that balance cash flow considerations with supplier trust.

• Conduct Comprehensive Supplier Qualification: Evaluate potential suppliers based on regulatory compliance (FDA, WHO-GMP certifications), production capacity, quality control measures, and past performance in international markets.

• Monitor Regulatory and Market Developments: Stay informed about changes in international trade regulations, patent expirations, and market trends to adapt sourcing strategies proactively.

By leveraging India's manufacturing advantages and implementing these strategic recommendations, UAE buyers can effectively source high-quality antidandruff formulations to meet market demands.

1. Gulf Health Council (GHC) Registration Verification: Confirm that the Indian manufacturer is registered with the GHC, ensuring compliance with GCC standards for pharmaceutical products.

2. Good Manufacturing Practice (GMP) Certification: Obtain a valid GMP certificate from the manufacturer, issued by the Central Drugs Standard Control Organisation (CDSCO) in India, to verify adherence to quality manufacturing standards.

3. Drug Master File (DMF) Review: Request and assess the DMF to understand the formulation, manufacturing process, and quality controls of the antidandruff product.

4. Quality Management System (QMS) Evaluation: Ensure the supplier has a robust QMS in place, encompassing quality control, assurance, and risk management protocols.

5. Regulatory Compliance Documentation: Verify that the manufacturer complies with the revised Schedule M of the Drugs and Cosmetics Act, which aligns with WHO-GMP standards.

6. Product Registration Status: Confirm that the antidandruff formulation is registered with the UAE Ministry of Health and Prevention, facilitating legal importation and distribution.

7. Stability Data Assessment: Review stability studies conducted under ICH guidelines to ensure the product maintains efficacy and safety throughout its shelf life.

8. Supply Chain Transparency: Obtain detailed information about the supply chain, including sourcing of raw materials and logistics, to ensure traceability and quality control.

9. Adverse Event Reporting Mechanism: Confirm the existence of a system for monitoring and reporting adverse events associated with the product, ensuring patient safety.

10. Insurance Coverage Verification: Ensure the manufacturer holds adequate liability insurance to cover potential product-related issues.

1. Certificate of Analysis (CoA): Provides detailed results of laboratory testing for a specific batch, confirming the product meets predefined specifications.

2. Certificate of Origin (CoO): Certifies the country where the product was manufactured, essential for customs clearance and verifying the authenticity of the product's origin.

3. GMP Certificate: Issued by CDSCO, this document confirms the manufacturing facility complies with Good Manufacturing Practices, ensuring consistent product quality.

4. Stability Data Reports: Demonstrates the product's stability over time under various environmental conditions, ensuring efficacy and safety throughout its shelf life.

5. Batch Manufacturing Records: Detailed documentation of the production process for each batch, ensuring traceability and adherence to manufacturing protocols.

6. Drug Master File (DMF): Comprehensive document detailing the manufacturing process, controls, and specifications of the product, providing insight into quality and safety measures.

7. Free Sale Certificate: Issued by CDSCO, this certificate indicates that the product is approved for sale in India, suggesting compliance with local regulatory standards.

8. Insurance Certificates: Proof of liability insurance coverage, protecting against potential claims related to product quality or safety issues.

9. Product Registration Certificate: Evidence that the product is registered with the UAE Ministry of Health and Prevention, authorizing its importation and sale within the UAE.

10. Adverse Event Reporting Procedures: Documentation outlining the system in place for monitoring, reporting, and addressing adverse events associated with the product.

1. Regulatory Non-Compliance: Recent FDA warning letters or WHO-GMP suspensions indicate serious compliance issues. For instance, in January 2024, India's Health Ministry revised GMP rules to align with global standards, highlighting the importance of compliance.

2. Unusually Low Pricing: Prices significantly below market rates may suggest compromised quality or substandard manufacturing practices.

3. Lack of Stability Data: Inability to provide comprehensive stability studies raises concerns about the product's shelf life and efficacy.

4. Limited Export History: No track record of exports to GCC or Middle East markets may indicate unfamiliarity with regional regulatory requirements.

5. Resistance to Audits: Hesitation or refusal to allow factory audits suggests potential issues with manufacturing practices or facility conditions.

6. Inadequate Quality Management Systems: Absence of a robust QMS can lead to inconsistent product quality and increased risk of defects.

7. Negative Industry Reputation: Reports of previous quality issues, recalls, or legal actions against the manufacturer are significant red flags.

8. Non-Compliance with Revised Schedule M: Failure to adhere to the updated Schedule M, which incorporates WHO-GMP standards, indicates non-compliance with essential quality regulations.

1. Pre-Audit Desktop Review: Conduct a thorough review of the manufacturer's documentation, including licenses, certifications, and quality control records, to identify potential areas of concern.

3. Post-Audit Corrective Actions: Document any deficiencies identified during the audit and require the manufacturer to implement corrective actions within a specified timeframe, ensuring continuous improvement.

4. Annual Re-Qualification Process: Schedule yearly audits to verify ongoing compliance with GMP standards and address any emerging issues promptly.

5. Remote Monitoring Options: Utilize technology such as live video inspections and digital documentation reviews to conduct remote audits, especially when travel is restricted.

By adhering to this structured approach, United Arab Emirates companies can ensure the qualification of reliable Indian suppliers for antidandruff formulations, maintaining high standards of product quality and regulatory compliance.